Cargando…

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX multiplexed tissue imaging and RNA sequencing...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Darci, Matusiak, Magdalena, Gutierrez, Belén Rivero, Bhate, Salil S., Barlow, Graham L., Jiang, Sizun, Demeter, Janos, Smythe, Kimberly S., Pierce, Robert H., Fling, Steven P., Ramchurren, Nirasha, Cheever, Martin A., Goltsev, Yury, West, Robert B., Khodadoust, Michael S., Kim, Youn H., Schürch, Christian M., Nolan, Garry P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602403/
https://www.ncbi.nlm.nih.gov/pubmed/34795254
http://dx.doi.org/10.1038/s41467-021-26974-6
Descripción
Sumario:Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced CTCL patients enrolled in a pembrolizumab clinical trial (NCT02243579). We find no differences in the frequencies of immune or tumor cells between responders and non-responders. Instead, we identify topographical differences between effector PD-1(+) CD4(+) T cells, tumor cells, and immunosuppressive Tregs, from which we derive a spatial biomarker, termed the SpatialScore, that correlates strongly with pembrolizumab response in CTCL. The SpatialScore coincides with differences in the functional immune state of the tumor microenvironment, T cell function, and tumor cell-specific chemokine recruitment and is validated using a simplified, clinically accessible tissue imaging platform. Collectively, these results provide a paradigm for investigating the spatial balance of effector and suppressive T cell activity and broadly leveraging this biomarker approach to inform the clinical use of immunotherapies.